It has been recently demonstrated that activated Hageman factor is digested by plasmin to yield prealbumin fragments (1) which convert prekallikrein to kallikrein, the enzyme that cleaves kininogen to yield bradykinin (2, 3). A relation between this kinin-forming system and the complement sequence exists in terms of both the inhibitor of the first component of complement (CiINH), 1 which inhibits both the first component (CI) ~ and kallikrein (4, 5), as well as plasmin (6) and the active Hageman factor (7), and the anaphylatoxin inacti-
vator, an enzyme which removes the C terminal arginine residue from the C3a and C5a fragments of the third (C3) and fifth (C5) components of complement as well as from bradykinin (8) . Kallikrein not only cleaves the permeability factor bradykinin from kininogen but also is itself specifically chemotactic for human neutrophils (9) , thus affording two of the essential ingredients of the inflammatory response. An additional function of the kinin-forming system iS to yield a fragment which profoundly alters the function of fully activated Ci. Fragment treatment of isolated, fully activated Ci, or partially activated CI, in whole human serum markedly enhances the hemolytic efficiency of Ci, in the latter instance without additional activation. Further, fragment-treated CI interacts with the fourth (C4) and the second (C2) components of complement to achieve a much greater inactivation of the third component than is accomplished by Ci, C4, and C2 in the absence of the fragment.
Materials and Methods
The sources and methods of handling of sheep erythrocytes, guinea pig sera, and human sera were as described (10) . Veronal-buffered saline, pH 7.5, ionic strength 0.145, containing 0.1% gelatin, 0.00015 ~ Ca ++, and 0.0005 ~ Mg ++ (GVB++), dextrose-Veronal-buffered saline, ionic strength 0.075 (DGVB++), and 0.01 ~ or 0.04 M disodium ethylenediaminetetraacetate (EDTA) were prepared as described (11) . The sources and methods of preparation of diethylaminoethyl-(DEAE-) and carboxymethyl-(CM-) cellulose, Sephadex G-200 and G-150 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.), hydroxylapatite, and the buffers used for chromatography have previously been reported (11) (12) (13) . Para-tosyl-L-arginine methyl ester hydrochloride (TAMe) and N-acetyl-L-tyrosine methyl ester (ATMe) were purchased from Mann Research Labs, Inc., New York; N-a-acetylglycyl-L-lysine methyl ester acetate (AGLMe) and N-acetyl-L-arginine methyl ester hydrochloride (AAMe) were obtained from Cyclo Chemical Corp., Los Angeles, Calif. Soybean trypsin inhibitor (SBTI) was obtained from Worthington Biochemical Corp., Freehold, N. J.
Preparation and Assay of Human Complement
Components.--C1 was prepared from pooled human serum by low ionic strength precipitation at pH 7.5 (11, 14) with the addition of Ca ++, 0.00015 •; further purification was achieved by Sephadex G-200 gel filtration (12) . The Ci preparation eluted with the 19S protein peak and it was found to be fully activated (14) . C4 and C2 were prepared by DEAE-and CM-cellulose chromatography (5, 11) . C3 and C5 were isolated from DEAE-cellulose chromatography (11) and further purified by hydroxylapatite column chromatography (15, 16) . The sixth (C6), seventh (C7), eighth (C8), and ninth (C9) components of human complement were obtained from Cordis Corp., Miami, Fla. C1 gp and C2 gp were prepared as described (11) .
Sheep erythrocytes were coated with commercial anti-sheep hemolysin made in rabbits (EA). EAC1 gp cells were prepared by mixing EA in DGVB ++ with an equal volume of activated first component of guinea pig complement (CigP), diluted to provide 250 effective
molecules/cell in the fluid phase; after incubation at 0 C for 45 min, the cellular intermediate was washed three times in DGVB ++ and stored in the same buffer with penicillin and streptomycin (11) . EAC4 were prepared from the EACi gp ceils (17) and further incubated in 0.01 M EDTA-GVB (18) . EACI'-4 cells were prepared by exposing EACT~ cells to C1 gv (18) . The procedures for the effective molecule titrations of Ci (19) , CIINH (20) , C4 (18), C2 (21), and C3 (22) were performed as described. The number of Ci molecules bound to a cell (EAC1) was determined by Ci transfer (23) .
Purification and Assay of the Components of the Kinin-Forming System.--35 ml of serum
were dialyzed overnight at 4°C in 0.01 ~ phosphate buffer at pH 7.8, and the precipitate formed was removed by centrifugation. The supernatant was applied to a 3.5 )( 30 cm DEAEcellulose column equilibrated with 0.01 ~ phosphate buffer, pH 7.8, followed by washing with the equilibrating buffer and elution with a linear salt gradient to 0.3 za NaC1. The initial protein peak (OD 280 m~) containing IgG, kallikrein, and plasma thromboplastin antecedent (PTA) was concentrated by ultrafiltrafion using a UM-10 membrane (Amicon Corp., Lexington, Mass.) to 5-10 ml, and was then further concentrated by wall vacuum using collodion bags, number 100, (Schleicher & Schuell, Inc., Keene, N. H.) to a final volume of 2 ml. This material was applied to a 2.5 )< 150 cm Sephadex G-150 superfine column equilibrated with 0.02 ~a tris (hydroxymethyl) aminomethane (Tris) chloride pH 7.6. The pattern was developed by upward flow at 5 ml/hr and 2.5 ml fractions were collected. Heat-inactivated plasma prepared by heating fresh plasma at 61°C for 2 hr and dialyzing overnight against 0.15 ~t NaC1 was used as a substrate for kallikrein (24) . Kallikrein activity was determined by incubating between 0.05 and 0.2 ml of enzyme source with 0.2 ml of substrate for 2 rain at 37°C and measuring the bradykinin generated by adding the mixture to the organ bath containiug the guinea pig ileum used for bioassay. Control tubes containing the enzyme source or the substrate were evaluated separately for bradykinin generation. The kallikrein peak was pooled, concentrated, and its purity assessed by disc gel electrophoresis at pH 9.3 (Buchler Instruments, Inc., Fort Lee, N. J.) (25) and by electro-focusing in 4% polyacrylamide gels (26) . In each instance a single broad band was obtained representing a mixture of kallikrein, IgG, and trace contamination with PTA. The shortening of the partial thromboplastin time of PTA-deficient plasma was used to assay for PTA. 0.05 ~ ml of PTA source was incubated for 2 rain at 37°C with 0.05 ml cephalin (6 mg/ml) and 0.05 ml PTA-deficient plasma in siliconized glass tubes. 0.05 ml 0.05 ~ CaCI2 was added, and the clotting time determined at room temperature. The tubes were tilted each minute and the end point defined as the time required for the clot to adhere to the glass tube.
P[asmin was measured by digestion of azocasein as described by Hummel et aI. (27) . Kininogen was prepared as previously described by Spragg et al. (3) .
For the esterolytic assay of kallikrein, each synthetic substrate was dissolved in 0.08 M phosphate buffer, pH 7.8, ionic strength 0.14. Esterolytic activity was measured by a modification of the colorimetric method described by Siegelman et al. (28) . 0.2 ml of enzyme was incubated with 0.8 ml of substrate in phosphate buffer at a concentration of 10 mmoles/ml. At 1 min and 31 min at 37°C, 0.4 ml of enzyme-substrate mixtures were removed and transferred to small tubes containing 0.25 ml of 15% trichloroacetic acid (TCA), and the precipitate formed was removed by centrifugation. 0.05 ml of 2% potassium permanganate (KMnO4), 0.05 ml of 10% sodium sulfite (Na2SO3), and 2 ml of chromotropic acid were added in sequence to 0.25 ml of supernatants, followed by incubation in a boiling water bath for t5 min. The purple color developed by the interaction of the methanol, derived from the splitting of the ester substrates with chromotropic acid, was measured in the spectrophotometer at 580 m~. The values were compared with those of a standard curve of methanol and the results calculated as millimoles per liter of methanol liberated in each reaction mixture during the 30 min incubation at 37°C.
RESULTS

Enhancement of the C] Hemolytic Activity by Fractions with Kinin-Generating Capacity
Aliquots of 0.5 ml of C1 containing 1000 units/ml were incubated with 0.1 ml DGVB ++ or 0.1 ml of five individual pools of fractions eluted from a DEAE-cellulose column during the purification of the enzyme kallikrein. Control samples of 0.5 ml DGVB ++ received 0.1 ml of each of the pools. The mixtures were incubated at 30°C for 30 rain and the Ci hemolytic activity of each sample measured.
Five areas capable of generating bradykinin with fresh plasma were observed as previously described (29) (Fig. 1) . The first peak, eluted with the starting buffer, contains IgG globulin, PTA, and releases bradykinin from either fresh plasma, heat-inactivated plasma, or purified kininogen (29) and therefore contains kallikrein activity. The second peak contains activated Hageman factor, and peaks three, four, and five represent fragments of active Hageman factor of progressively smaller size and net negative charge (29) . Plasminogen and plasmin overlap peaks two and three. Enhancement of the Ci hemolytic activity was observed with the first and fourth peaks, while peaks two, three, and five were negative in this regard. Ci was precipitated in the step which preceded chromatography of the supernatant and no CI hemolytic activity was demonstrable in any of the five kinin-generating peaks.
The Ci enhancement produced by the kallikrein-rich peak 1 was further analyzed in terms of its dose response effect.
Aliquots of 0.5 ml of Ci containing 1000 units/ml were incubated with DGVB ++ or seven increasing amounts (0.01M).I ml) of peak 1. The final volume of a]l the mixtures was brought to 0.6 ml. A control sample of 0.5 ml DGVB ++ received 0.1 ml of peak 1. The mixtures were incubated at 30°C for 30 rain and the C1 hemolytic activity measured in each sample.
As shown in Fig. 2 , the Ci activity increased from 1000 units/ml in the control sample to 2500 units/ml with increasing amounts of peak 1, at which point a plateau of Ci enhancement was reached. The kallikrein peak incubated with buffer alone was free of CI hemolytic activity.
Five 0.5 mI samples of Ci diluted to contain 1000 units/ml received different additions during a total incubation time of 40 rain. The respective additions were 0.01 ml of a concentrated peak 1, 0.01 ml SBTI 0.1 mg/ml, peak 1 followed by SBTI for 30 rain, SBTI followed by peak 1 for 10 min, or buffer. In a sixth sample 0.01 ml peak 1 and 0.01 ml SBTI were incubated for 10 rain before receiving 0.5 ml C1. The final volume of all samples was brought to 0.62 ml with buffer. The results are depicted in Fig. 3 . SBTI did not influence the Ci hemolytic activity alone (B). Peak 1 increased the Ci hemolytic activity 300 % (C); the increase was limited to 125 % when peak 1 was previously incubated with SBTI (D). The SBTI has a lesser effect when its preincubation with kallikrein was omitted (E), and has virtually no effect when added after the interaction of CI with peak 1 (F). This suggests that the enhancement was due to a SBTIsensitive proteolytic enzyme such as kallikrein.
Accordingly, in a separate experiment the dose response of the effect of SBTI on TAMe hydrolysis, and kinin formation as well as CI enhancement, was examined.
Five duplicate samples of SBTI containing 10, 1, 0.1, 0.01, and 0.001 mg/ml in saline were incubated with an equal volume of buffer or peak 1. A control sample of peak 1 received buffer alone. After I0 rain at 30°C the samples were analyzed.
Inhibition of kinin generation was slightly more sensitive to SBTI than the splitting of the synthetic substrate; 50% inhibition was achieved with 0.0050 mg and 0.0075 mg of SBTI respectively. In contrast almost 100 times as much SBTI (0.5 rag) was required to achieve 50% suppression of CI enhancement, suggesting that the enhancing activity may reside in a structure other than the active enzymatic site of a TAMe esterase such as kallikrein. Attention was therefore focused on the possibility that the CI-enhancing material in peak 1 was somehow related to the more negatively charged material observed in peak 4 (rig. 1). Fio. 3. Inhibition by SBTI of the Ci enhancement produced by peak 1. CI incubated with DGVB ++ (A), Ci incubated with SBTI (]3), CI incubated with peak 1 (C), peak 1 incubated with SBTI before the addition of C1 (D), Ci incubated with SBTI before the addition of peak 1 (E), and C1 incubated with peak 1 before the addition of SBTI (F).
Recognition of a C1-Enhaneing Material Apparently Derived from the Kallikrein-Containing Fraction
Peak 1 of the DEAE-cellulose column was subjected to Sephadex G-150 gel filtration. The fractions were combined into eight pools, concentrated by pressure dialysis to a final volume of 10 ml, and tested for kilfin formation on heated plasma and for CI enhancement by their effect on C[, 1000 units/ml.
As shown in Fig. 4 , a protein peak produced largely by IgG was found in fractions 120-160; superimposed on the descending portion of this peak was bradykinin-generating activity, attributable entirely to kallikrein at approximately 45 % of the column bed volume. A peak of CI-enhancing activity was observed in the same position. A second peak of CI enhancement was present at approximately 80% bed volume. This material designated Kf was devoid of kinin-generating activity from either fresh or heat-inactivated plasma, indicating that neither kallikrein nor the active Hageman factor fragments was present. Rechromatography of the material corresponding to 45 % of the bed volume again yielded Ci-enhancing activity at 45 and 80 % bed volume, with the same characteristics as observed in the initial chromatogram.
In order to determine whether or not Kf represents some portion of the Ci molecule, it was examined for the esterolytic and proteolytic characteristics of Ci. The ability of Kf to hydrolyze synthetic substrates was studied in an experiment in which 0.2 ml samples of Kf were incubated with 0.8 ml of TAMe, ATMe, AAMe, and AGLMe containing 10 mmoles of substrate/ml. Kf did not hydrolyze any of the synthetic substrates studied. The capacity of Kf to destroy C4 and C2 in the fluid phase was determined by incubating 0.1 ml samples of Kf with 0.5 ml of C4 containing 1000 units/ml, or C2 containing 100 units/ml, or with buffer. After 30 rain at 30°C the residual C4 and C2 were measured in each sample. 90 and 30% of C4 and C2 respectively were destroyed by Ci while Kf failed to inactivate these two components in the fluid phase.
The heat stability of Kf at 56°C was evaluated in terms of Ci enhancement. When plotted logarithmically there was a linear loss of activity with a halflife of 35 rain. The pH stability of Kf was examined in a range of 4-9 by adding 0.1 M HC1 or 0.1 M NaOH to the Tris chloride buffer. After 1 hr the pH in each sample was brought to 7.5 and the final volume adjusted to 1 ml with buffer. At pH's 4, 5, and 6 there was a 20% loss in Ci-enhancing capacity, while there was no loss between pH 7 and 9.
Effect of Kf on Cell-Bound Functions of C1
Utilization of C2 by EAC14 and EAC1Kf4.--Two 0.5 ml samples of C[ containing 1800 units/ml were incubated with 0.1 ml of either buffer or Kf. A control sample of Kf received 0.5 ml buffer. After 30 rain at 30°C, the C1 hemolytic activity was measured in all samples. C1 incubated with buffer contained 1800 Ci units, that incubated with Kf exhibited 4300 units, and Kf alone was devoid of any hemolytic activity. These three samples were diluted to the same final dilution (1:18). Two aliquots of EACZt cells 1 X 10S/ml were incubated with an equal volume of the diluted C1 and the third aliquot of cells with C1Kf. After 15 min at 30°C, the samples were centrifuged and washed in DGVB ++. One of the EACI'4 preparations and the EAC1Kf4 intermediate were resuspended in buffer, while the other EAC 14 was resuspended in the diluted Kf. All samples were incubated 15 min at 30°C, centrifuged, washed once in buffer, and resuspended to the original cell concentration. 10 ml of each cellular intermediate prewarmed at 30°C received 10 ml of C2, 1.2 units/ml, and the incubation was continued. 1 ml samples were removed at time intervals up to 15 rain, added to 1.5 ml of guinea pig sera diluted 1:22.5 in 0.04 M EDTA (GPC-EDTA), and the reaction developed for 60 rain at 37°C.
The results (Fig. 5) show that the EACI'-4 generated with untreated Ci followed by treatment with buffer or Kf had a Tm~ of 4.5 min with a maximal hemolytic activity (Zm~) with C2 of 0.85 and 0.95 SAC142 respectively, while EAC1Kf4 had a Tm~ of 3 rain and a Zm~ of 1.98 SAC1Kf42. The results were similar in a subsequent experiment even when the CiKf was diluted more than the Ci so as to achieve a comparable number of Ci hemolytic units, that is Kf shifted the Tm~x from 3.5 rain to 1.75 rain and the Zm~x from 0.85 to 1.59 sites.
Interaclion of C1 and C1Kf with EA C712. -
An EAC42 intermediate was generated to provide cells with bound unactivated C2. EACZt cells, 1 X 109/ml, in DGVB ++ at pH 8.5, with a final Mg ++ concentration of 0.001 M, were incubated with an equal volume of C2 diluted in the same buffer to contain less than 1 C2 unit when tested with routinely prepared EAC14 cells. The mixture was incubated at 30°C for 30 min, centrifuged at room temperature, washed once, and resuspended in the same buffer to the original volume. The buffers used for washing and resuspension were prewarmed at 30°C. Activation of these EAC42 cells was obtained by incubating these cells with aliquots of Ci or C1Kf described above diluted to contain 5, 20, and 50 C1 units/ml. 9 ml of C1 and C1Kf dilutions were prewarmed at 30°C, and each received 1 ml of EAC42 cells, 1 X 109/ml. A sample of EAC42 was incubated with Kf without C1. Upon mixing and at time intervals up to 20 rain, 1 ml samples were removed and added to 1.5 ml of GPC-EDTA. The reaction was developed at 37°C for 60 min. Fig. 6 shows that untreated Ci produced 0.42, 0.57, and 0.65 SAC142 with a Tm~ of 7, 3, and 2.75 rain respectively with the three Ci concentrations used, while CiKf at the same concentrations formed 1.35, 1.5, and 1.6 SAC1Kf42, with a Tm,x of 3.25, 1.75, and 1.75 rnin respectively. Thus for the same input of hemolytic units, CIKf generated cells with a shorter Tm~ and a higher Zm~, than untreated Ci, even when the unactivated C2 was already bound to the cell.
E~ecl of Kf on C1 Binding.-
Two aliquots of C[ and CiKf were diluted in either DGVB ++ or GVB ++ to contain 20 units of C[ each. 9 ml of these four C1 preparations, prewarmed at 30°C, received 1 ml of EAC42 cells, 1 X 109. The mixtures continued to be incubated at 30°C, and at time intervals up to 20 min 1 ml samples were rernoved and added to 1.5 ml of GPC-EDTA.
The results, Fig. 7 , show that in DGVB~+ Ci formed 0.58 SACI-~, with a Tm~ of 3.5 rain; 0.85 SACI-~ were measured in GVB ++ with a T, .... of 5 rain. In contrast CIKf in DGVB ++ generated 1.7 SAC1Kf42 with a Tm~ of 1.5 rain, but only 1.1 SAC1Kf42 in GVB -H-with a T,x,~ of 3.5 rain, suggesting that the effect of Kf was not to create a form of Ci capable of moving about the cell. This point was further investigated in an experiment in which cell-bound CI and CIKf were compared after washing the cells.
Two samples of Ci treated either with buffer or Kf were serially diluted in DGVB ++, 1/2000-1/32,000. Duplicate 0.5 ml samples of Ci or CiKf received 0.5 ml of EAC7~ to generate EAC14. After 30 min at 30°C, one series of EAC14 and EAC1Kf4 samples was centrifuged, washed once in DGVB -~+, and resuspended in 1 ml DGVB++; the duplicate series of samples was kept unwashed The reaction mixtures were developed with (;2 and GPC-EDTA.
The results indicated that CiKf generated significantly more hemolytically active sites (12,800 units/roll than Ci (1820 units/roll and that these sites tolerated washing (8450 units/roll at least as well as those generated without Kf (845 units/roll.
Attention was next directed to the capacity of the effect of Kf to be transferred.
C1 and C1Kf containing 3850 and 20,0(t0 units/ml respectively were both diluted in DGVB ++ to contain 20 units/ml. Aliquots of each sample were incubated with an equal volume of EA, 1 X 10S/ml. After 30 rain at 30°C and 15 min at 0°C, both reaction mixtures were centrifuged, and the C1 present in both supernatants measured. The cells were resuspended to their original volume in DGVB ++ and the number of C1 molecules bound to the EA determined by transfer of Ci from dilutions of the EAC1 and EAC1Kf in GVB ++ to EAC4 cells, 1 X l0 s. In addition, dissociation of C1 or CiKf at low ionic strength was also measured by transfer.
The results show that of the 20 Ci units/ml added to the EA, 5 units were found in the supernatant and 14 units on the cells as assessed by transfer in GVB ÷+. In contrast with Kf-treated Ci only 0.6 units were found in the supernatant and 10 units by transfer. Although only half of the CiKf input was recovered, the hemolytic activity observed must represent enhanced Ci molecules since the initial dilution of CIKf was five times greater than that of the starting C1; if enhancement had disappeared during the transfer only 4 Ci hemolytic units would have been expected. The undetected activity could have either been lost because of disappearance of the Kf effect, or not have been susceptible to transfer because of persistent binding to the donor cell. Neither Ci nor CIKf transferred well in DGVB ++, Ejfect of Kf on C1 Activation.--Two 2 ml aliquots of C1 prepared as previously described (14) and C1 each containing 1000 units/ml were incubated with 0.1 ml Kf or buffer. At 0 time and 5 rain intervals up to 60 min 0.01 ml samples were removed and diluted 1 : 1000 in DGVB ++. 0.5 ml samples of each dilution were immediately added to 0.5 ml EACJ,2 cells, 1 X 10S/ml. The samples were incubated for 15 min at 30°(; and developed with GPC-EDTA. C[ incubated with buffer produced the formation of 0.32 SACI4~ at 0 time and 0.45 SACI-~ at the end of 60 min incubation; incubation with Kf increased the hemolytic activity to 0.75 SAC1Kf42 at 0 time and 1.02 SAC1Kf42 at 60 min.
C1 incubated either with buffer or Kf failed to prepare the EAC42 intermediate for lysis. The lack of effect of Kf on C1 indicated that its action is restricted to already activated Ci molecules.
C3 Utilization by C3 Convertase Generated by C1 and C1Kf.--
Two batches of EAC4 ceils were converted to EAC1-4 and EAC1Kf4 by incubation with either C1 or CiKf diluted to contain 15 units/ml. The cells were washed and resuspended in DGVB ++. 0,5 ml aliquots of C3 diluted to contain 50 units/ml were incubated with 0.5 ml of the intermediate 1 X 108/rul or with buffer. All samples received 0.5 ml C2 containing 100 units/ml. After 30 rain at 30°C the cells were sedimented and the C3 in the supernatant fluid was measured. in the supernatant after incubation with EAC142 cells, and only 22 were detected in the sample incubated with the EAC1Kf42 intermediate.
Effect of Kf on Fluid Phase Functions of C-]
Fluid l~hase Destruction of C4 by C1 and CTKf.--Two aliquots of C1 were incubated either with buffer or Kf and a sample of Kf was incubated with buffer alone. Untreated Ci containing 400 units/mI and Kf-treated CI exhibiting 1900 units/ml were diluted to contain 50 units/ml. Four aliquots of a single dilution of C4 containing 1300 units/ml were incubated with either buffer, Kf, C1, or C1Kf. After 30 rain at 30°C the residual C4 was measured in each reaction mixture.
Of the 1300 units present in the samples incubated with buffer or Kf at the end of the experiment (Fig. 9) , 600 units were destroyed by CI, while only 50 were destroyed by the same number of Ci hemolytic units present in the CiKf sample.
Fluid Phase Destruction of C2 by CIKf in the Presence and Absence of C4.--
Samples of C1 and C1Kf were diluted to contain 100 units/ml each. Four duplicate 0.5 ml samples of C2 containing 20 units/ml were incubated with 0.5 ml of either buffer, Kf, C1, or CIKf. One sample of each mixture received 0.5 ml C4, 100 units/ml, the other, 0.5 ml buffer. After 30 min at 30°C, the residual C2 in each sample was measured. Residual C4 in samples incubated with bufferw 11 units were destroyed by CI, while CIKf inactivated 3 C2 units. Of the 18 units detected in the mixture of C2 and C4, 16 were destroyed when CI was added and only 3 when CiKf was present (Fig. 10) . Kf alone did not have an effect on either C4 or C2 alone or in combination.
Effect of Kf on Human Sera
In order to examine the effect of Kf on C1 and CI which has not been subjected to chromatographic separation, studies were carried out in normal human sera and in serum from a patient with hereditary angioedema (HAE), deficient in the CIINH.
Two 0.5 ml samples of serum from a patient with HAE, diluted 1:200 in DGVB ++, were incubated with 0.1 ml Kf or 0.1 ml buffer. After 30 min at 30°C the C1 activity was measured in dilutions of both samples. The C1 titer in the sample incubated with buffer was 146,000, while incubation with Kf enhanced the C1 activity to 212,000 units/ml.
Although this experiment clearly showed that Kf acted upon C1 in whole serum, it failed to demonstrate whether this effect involved activation of C1, or was only because of an effect on the already activated CI molecules, and thus this point was further examined.
Normal human serum and HAE serum were diluted 1 : 100 in DGVB ++. Two 2 ml samples of both diluted sera were incubated at 30°C; one sample of each received 0. 
DISCUSSION
Several years ago a material associated with a partially purified preparation of human kallikrein (30) was recognized as being capable of enhancing the hemolytic activity of fully activated first component of human complement. In the present studies chromatography of human serum to yield the active enzymes of the kinin-forming sequence again revealed an association between the kallikrein-containing fraction and Ci enhancement (Fig. 1) . Peak 1 containing kallikrein also contains IgG and PTA (1, 31) . PTA can be partially separated from kallikrein and the Ci-enhancing material by Sephadex G-150 gel filtration (Fig. 4) . The kallikrein-rich fraction enhances Ci hemolytic activity in a dose response fashion (Fig. 2) and its effect is reversed by pretreatment of the kallikrein with SBTI (Fig. 3) . The concentration of SBTI required to prevent CI enhancement is 100 times greater than that necessary to suppress kinin generation or esterase activity; it may well be that the enhancement of C] activity by the kallikrein-rich peak 1 is not directly due to interaction with the active enzymatic site of kallikrein. SBTI does not inhibit PTA (32) .
It is noteworthy that the DEAE-cellulose chromatography of serum ( Fig. 1 ) revealed a second region of Ci-enhancing activity in an area known to contain partially digested Hageman factor fragments but not kallikrein (1, 29) . In addition further chromatography and rechromatography of the kallikrein-rich material by Sephadex gel filtration revealed a continual shift of Ci-enhancing capacity to material of a molecular weight considerably less than kallikrein (Fig. 4) , designated Kf. Kf was distinguished from the Hageman factor fragments by its failure to generate bradykinin from fresh plasma, and from kallikrein by its inability to produce bradykinin from heat-inactivated plasma. The lack of activity against such synthetic amino acid esters as AAMe, TAMe, AGLMe, or ATMe not only further distinguishes Kf from kallikrein but also from the subunits of CI, Cir, and CIs (33) . It is differentiated from Clq on the basis of gel filtration and chromatographic characteristics (34) .
The enhancement of CI function by Kf could be because of activation of unrecognized precursor molecules, reactivation of active molecules which have somehow decayed, or an increased efficiency of already active Ci molecules. There is no evidence that Kf will activate isolated precursor C1 or C1 in normal serum or serum from a patient with HAE devoid of CIINH (Fig. 11 ). An effect of Kf to reduce the binding of Ci could create an apparent increase in efficiency b__y permitting the molecule to move about the cell so as to create multiple active 42 sites; however in contrast to Ci, CiKf demonstrated a reduction of Tmax and Zm~ upon interaction with EAC42 cells in GVB ++ (Fig. 7) . Further, the EAC1Kf4 intermediate tolerated washing in a manner similar to the EAC14 intermediate. CiKf tolerated transfer and there was again no evidence of increased dissociability.
The effect of Kf on Ci was demonstrable only when the interaction occurred in the fluid phase before interaction with the cellular intermediate. When CIKf was interacted with an EAC4 cell, and the reaction was brought to completion by the addition of C2 and the terminal components, the Tm~ was shorter and the Zm~ greater than when Ci was used either at a comparable dilution of starting CI (Fig. 5 ) or in terms of the same number of apparent hemolytic units. When Ci and CiKf of comparable hemolytic activity were examined for their capacity to activate a site on the EACTI2 intermediate, C1Kf again yielded a shorter Tin= and a greater Zm,~ than was achieved by the introduction of Ci (Fig. 6) . The capacity of C1Kf to yield a greater Znl~ and a shorter Tr,~ than CI even when employed at a greater dilution so as to contain comparable hemolytic activity in a CI titration suggests that the effect of Kf is to yield a more efficient molecule and not reactivate molecules which have somehow lost their activity, unless such reactivated molecules are more efficient than those still in the starting state.
That Kf does indeed lead to a functionally altered form of Ci is supported by finding that fluid phase C4 and C2 are spared from inactivation (Figs. 9 and 10). If failure to rapidly inactivate is synonymous with more efficient utilization of C4 and C2, then the capacity of C1-Kf to activate cell-bound 742 (Fig. 6) to give a shorter Tm~ and a greater Z .... than Ci would be expected.
Similarly the EAC1Kf4 intermediate would utilize fluid phase C2 to give a shorter Tm,x and Zm~x than the EAC14 intermediate as was observed (Fig. 5) . The view that C1Kf permits a more efficient utilization of C4 and C2 so as to generate more 42 sites as recognized by a shorter Tm~x and a greater Zm~ (Fig. 5 and 6 ) would be consistent with the finding of increased C3 inactivation by an EAC1Kf42 cell (Fig. 8) . SUMMARY An activity designated Kf can be separated from human serum and shown to give a 100-300% enhancement in the hemolytic activity of fully activated, fractionated C~I. The enhancement of Ci activity is not because of activation of precursor C1 and it is not attributable to an effect on Ci binding. EAC42 or EAC4 intermediates interacted with CIKf exhibit a greater T~x and shorter Zm~x than when such intermediates are reacted with the same number of hemolytic units of C1. C3 consumption by the EAC1Kf42 intermediate greatly exceeds that of the EAC14---2 intermediate produced from the same EACYi cells by comparable inputs of the other two complement components. Taken together, these findings suggest that Kf-treated CI achieves more efficient utilization of C4 and C2 to create a larger number of 42 sites as appreciated on the intermediates by shorter Tm,x and a greater Z~x, and an increased capacity to utilize C3. The capacity of Kf to enhance Ci upon introduction into whole serum of a patient with hereditary angioedema (HAE) in a manner comparable to its effect on fractionated CI suggests that the effect of Kf may be pertinent to certain pathophysiologic conditions of man.
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